Wietske Kievit

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent‐onset rheumatoid arthritis

Judith A.M. Wessels, S M van der Kooij, Saskia le Cessie et al. · Arthritis & Rheumatism · 2007 · 246 citations

Medicine, Pharmacology, Pharmacotherapy +13

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Noortje van Herwaarden, Aatke van der Maas, M.J.M. Minten et al. · BMJ · 2015 · 181 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

S. A. A. van Dartel, Jaap Fransen, Wietske Kievit et al. · Annals of the Rheumatic Diseases · 2012 · 146 citations

Medicine, Internal Medicine, Pharmacotherapy +14

Prior Colorectal Neoplasia Is Associated With Increased Risk of Ileoanal Pouch Neoplasia in Patients With Inflammatory Bowel Disease

Lauranne Derikx, Wietske Kievit, Joost P.H. Drenth et al. · Gastroenterology · 2013 · 134 citations · Full text

Medicine, Oncology, Surgery +15

The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data

Wietske Kievit, Eddy Adang, Jaap Fransen et al. · Annals of the Rheumatic Diseases · 2008 · 118 citations

Medicine, Clinical Sciences, Pharmacotherapy +14